Skip to content
Screener

Erasca, Inc. ERAS Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Pfizer logo
PfizerPFE
$3.41B-97.1%
Amgen logo
AmgenAMGN
$937M-15.5%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$1.72B+204%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$44.29M-58.8%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$93.08M+21.7%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788
Line itemMarch 31, 2026December 31, 2025
Total current liabilities26,66428,511
Operating lease liabilities, net of current portion40,70242,073
Other liabilities340399
Total liabilities67,70670,983
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2026 and December 31, 2025; 310,806,888 and 284,159,076 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively3128

Item 1. Financial Statements.

FAQ

What is Erasca, Inc.'s total liabilities?
Erasca, Inc. (ERAS) reported total liabilities of $67.71M in Q1 2026.
How has Erasca, Inc.'s total liabilities changed year-over-year?
Erasca, Inc.'s total liabilities decreased by 5.6% year-over-year, from $71.74M to $67.71M.
What is the long-term trend for Erasca, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Erasca, Inc.'s total liabilities has grown at a 32.5% compound annual growth rate (CAGR), from $17.4M to $70.98M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Erasca, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude